Clinical Trials Logo

Disease Severity clinical trials

View clinical trials related to Disease Severity.

Filter by:
  • None
  • Page 1

NCT ID: NCT06276829 Completed - Behcet's Disease Clinical Trials

Behçet and LDH/Albumin

Start date: February 1, 2020
Phase:
Study type: Observational [Patient Registry]

ABSTRACT Objective: To investigate whether the lactate dehydrogenase to albumin ratio can be used as a parameter to determine disease severity in Behçet's disease, an inflammatory disease, by comparing it to healthy controls. Patients and Methods: In this retrospective cohort study, patients with Behçet's disease aged 18-69 years who presented to the outpatient clinic between February 2020 and April 2023 and healthy individuals of similar age and gender were enrolled. LDH, albumin levels, and LDH/albumin ratio of both groups were compared. Clinical findings and characteristics of Behçet's patients and disease severity were recorded and analyzed in relation to LDH/albumin ratio.

NCT ID: NCT06041126 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

The Effect of Clinical Parameters on Muscle Oxygenation in Patients With COPD

Start date: April 24, 2023
Phase:
Study type: Observational

The aim of this study is to examine the peripheral muscle oxygenation of patients with Chronic Obstructive Pulmonary Disease at rest, during submaximal exercise and recovery, and to examine the effects of disease severity and respiratory functions on peripheral muscle oxygenations. In this study, the effect of disease severity and respiratory problems on peripheral muscle metabolism of patients with COPD will be explained.

NCT ID: NCT02199379 Completed - Renal Impairment Clinical Trials

A Phase 1, Open-Label, Single-Dose, Pharmacokinetic and Safety Study of E7080 (24 mg) Administered to Subjects With Mild, Moderate, and Severe Renal Impairment and to Healthy Subjects

Start date: November 2011
Phase: Phase 1
Study type: Interventional

The purpose of this multicenter, open-label, non-randomized, single, oral dose, sequential-cohort study was to determine pharmacokinetics and safety of lenvatinib (24 mg) administered to healthy subjects and to subjects with renal impairment.

NCT ID: NCT00567983 Completed - Disease Progression Clinical Trials

Topical Cyclosporine and Disease Progression

Start date: December 2007
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the effect Restasis has in regards to disease progression.